Human Genetic Signatures Pty Ltd
At Human Genetic Signatures, we design, develop and market a novel molecular diagnostics assay technology called 3base™ that simplifies the genomes of microbial targets, improving patient testing.
At Human Genetic Signatures, we design, develop and market a novel molecular diagnostics assay technology called 3base™ that simplifies the genomes of microbial targets, improving patient testing.Our 3base™ technology is adaptable to a broad menu of tests, the results of which assist in detecting the presence of viruses and bacteria and in the future, monitoring disease progression and guiding therapy.
Our latest product offering is a real time molecular assay for detection of Hypervirulent C. difficile bacteria. Our technology was behind the recent discovery that the epidemic strains 027 and 078 are present in New South Wales.With a primary focus on DNA methylation, Human Genetic Signatures was founded in 2001 by Dr Geoffrey Grigg, who prior to the inception of Human Genetic Signatures held the position of Chief of the Division of Molecular Biology at the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Australia. Dr Grigg was also a founder of listed biotechnology companies Cambridge Antibody Technology and Peptech.
Human Genetic Signatures is a nucleic acid technology company and we have invented and commercialised various novel technologies.
The most widely used method for methylation analysis, the bisulphite method, was invented by our founder Dr Geoffrey Grigg, and became our core focus in the early days of the business.
This method has since been substantially improved and is now owned by Human Genetic Signatures.
Notable amongst its developments are a high-throughput methylation screening platform (384 genes) and a revolutionary method for improved diagnostic testing for microbial pathogens.
As a result of our bisulphite work, we made an interesting discovery;
The treatment of microbial DNA by sodium bisulphite effectively reduces the four-base DNA code to three bases. We call this 3base™, and this treatment creates a synthetic genome that does not exist in the natural world that has universal applicability to molecular diagnostic assays.
Number of employees: 10
Main business focus/
Listing by sector:
- Infectious Diseases
- Medical Devices
|Contact person||Dr John Melki|
|Job Title||Senior Principal Research Scientist|
|State||New South Wales|
|Phone||61 2 9870 7580|
|Fax||61 2 9889 4034|